Filing Details
- Accession Number:
- 0001209191-22-045114
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-09 19:54:51
- Reporting Period:
- 2022-08-05
- Accepted Time:
- 2022-08-09 19:54:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1029142 | Dynavax Technologies Corp | DVAX | Pharmaceutical Preparations (2834) | 330728374 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1580849 | Robert Janssen | C/O Dynavax Technologies 2100 Powell Street, Suite 720 Emeryville CA 94608 | Senior Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-05 | 900 | $10.47 | 25,607 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-05 | 900 | $17.01 | 24,707 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-08-08 | 4,450 | $10.47 | 29,157 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-08 | 4,450 | $17.16 | 24,707 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-05 | 900 | $0.00 | 900 | $10.47 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-08 | 4,450 | $0.00 | 4,450 | $10.47 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 12,795 | 2026-02-21 | No | 4 | M | Direct | |
| 8,345 | 2026-02-21 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 15, 2021.
- This transaction was executed in multiple trades at prices ranging from $17.00 to $17.07; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- This transaction was executed in multiple trades at prices ranging from $17.00 to $17.43; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
- Not applicable.
Billionaire Hedge Funds
